- Home
- FSEA vs CUE Comparison
FSEA vs CUE Comparison
Compare FSEA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSEA
- CUE
- Stock Information
- Founded
- FSEA 1890
- CUE 2014
- Country
- FSEA United States
- CUE United States
- Employees
- FSEA N/A
- CUE N/A
- Industry
- FSEA Savings Institutions
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- FSEA Finance
- CUE Health Care
- Exchange
- FSEA Nasdaq
- CUE Nasdaq
- Market Cap
- FSEA 51.2M
- CUE 58.9M
- IPO Year
- FSEA N/A
- CUE 2018
- Fundamental
- Price
- FSEA $11.00
- CUE $0.78
- Analyst Decision
- FSEA
- CUE Strong Buy
- Analyst Count
- FSEA 0
- CUE 3
- Target Price
- FSEA N/A
- CUE $3.00
- AVG Volume (30 Days)
- FSEA 5.7K
- CUE 158.3K
- Earning Date
- FSEA 05-20-2025
- CUE 05-20-2025
- Dividend Yield
- FSEA N/A
- CUE N/A
- EPS Growth
- FSEA N/A
- CUE N/A
- EPS
- FSEA N/A
- CUE N/A
- Revenue
- FSEA $15,874,000.00
- CUE $9,287,000.00
- Revenue This Year
- FSEA N/A
- CUE N/A
- Revenue Next Year
- FSEA N/A
- CUE $25.99
- P/E Ratio
- FSEA N/A
- CUE N/A
- Revenue Growth
- FSEA 70.41
- CUE 69.16
- 52 Week Low
- FSEA $8.60
- CUE $0.45
- 52 Week High
- FSEA $11.69
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- FSEA 47.43
- CUE 46.03
- Support Level
- FSEA $10.80
- CUE $0.71
- Resistance Level
- FSEA $11.24
- CUE $0.78
- Average True Range (ATR)
- FSEA 0.16
- CUE 0.06
- MACD
- FSEA 0.00
- CUE 0.01
- Stochastic Oscillator
- FSEA 42.55
- CUE 46.11
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities, and bank-owned life insurance.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.